Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain

Abstract Alpha adrenergic receptor sites in mammalian brain tissue can be labeled by the binding of [3H]WB-4101 (2-([2′,6′-dimethoxy] phenoxyethylamino) methyl benzodioxan), a potent α-adrenergic antagonist. Numerous neuroleptic drugs of phenothiazine, butyrophenone and thioxanthene classes are potent in competing for [3H]WB-4101 binding, with affinities resembling those of classic α-antagonists such as phentolamine and phenoxybenzamine. The potencies of neuroleptics in competing for WB-4101 binding sites correlate closely with their potencies in antagonizing norepinephrine and epinephrine induced lethality in rats, confirming that affinity for WB-4101 binding sites predicts α-receptor antagonism in vivo. The relative affinities of neuroleptics for WB-4101 binding sites and for dopamine receptors as labeled by [3H]haloperidol provides an index of the relative propensities of these drugs for eliciting autonomic side effects such as orthostatic hypotension and sedation.

[1]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[2]  C. Niemegeers,et al.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. , 1965, Arzneimittel-Forschung.

[3]  S. Snyder,et al.  Beta adrenergic receptor binding in membrane preparations from mammalian brain. , 1976, Molecular pharmacology.

[4]  S. Snyder,et al.  Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. , 1977, Molecular pharmacology.

[5]  A. V. Christensen,et al.  The comparative pharmacology of flupenthixol and some reference neuroleptics. , 2009, Acta pharmacologica et toxicologica.

[6]  R. Noble,et al.  A QUANTITATIVE METHOD FOR THE PRODUCTION OF EXPERIMENTAL TRAUMATIC SHOCK WITHOUT HÆMORRHAGE IN UNANÆSTHETIZED ANIMALS , 1942 .

[7]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[8]  R. Lefkowitz,et al.  Alpha-adrenergic receptor identification by (3H)dihydroergocryptine binding. , 1976, Science.

[9]  J. Riehl,et al.  Chlorpromazine. III. The effects of chlorpromazine and chlorpromazine sulfoxide on vascular responses to L-epinephrine and levarterenol. , 1960, The Journal of pharmacology and experimental therapeutics.

[10]  H. Dale On some physiological actions of ergot , 1906, The Journal of physiology.

[11]  R. Ruffolo,et al.  Binding of [3H]dihydroazapetine to alpha-adrenoreceptor-related proteins from rat vas deferens. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Shader,et al.  Psychotropic drug side effects : clinical and theoretical perspectives , 1971, Psychological Medicine.

[13]  A. Dobkin,et al.  NEUROLEPTANALGESICS: A COMPARISON OF THE CARDIOVASCULAR, RESPIRATORY AND METABOLIC EFFECTS OF INNOVAN AND THIOPENTONE PLUS METHOTRIMEPRAZINE , 1963 .

[14]  S. Snyder,et al.  Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. , 1976, Molecular pharmacology.

[15]  S. Snyder,et al.  Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency , 1976, Nature.

[16]  S. Snyder,et al.  Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. , 1976, Molecular pharmacology.

[17]  S. Snyder,et al.  Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states. , 1976, Life sciences.